Is Mounjaro Bad for You? The Evidence-Based Safety Profile and Real Risk Assessment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) is not "bad for you" in absolute terms, but it carries specific risks that matter for specific people: contraindicated in patients with personal or family history of medullary thyroid carcinoma, associated with increased gallstone risk during rapid weight loss, and causes gastrointestinal side effects in 60-80% of patients during titration
• The SURPASS and SURMOUNT trials (combined N = 8,000+) show serious adverse event rates of 5.2% on tirzepatide vs 4.8% on placebo, a difference that is not statistically significant
• The question isn't whether Mounjaro is universally "bad" but whether the documented risks are acceptable for your specific medical profile and weight-loss goals
• Most safety concerns circulating online conflate transient side effects (nausea, which resolves) with serious adverse events (pancreatitis, which is rare but requires immediate care)

Direct answer (40-60 words)

Mounjaro is not inherently bad for you, but it is inappropriate and potentially dangerous for specific populations: those with personal or family history of medullary thyroid carcinoma, active pancreatitis, severe gastroparesis, or type 1 diabetes. For appropriate candidates, serious adverse events occur in roughly 5% of patients, comparable to placebo rates in clinical trials.

Table of contents

1. The safety question most people are actually asking
2. What the clinical trial safety data actually shows
3. The boxed warning: medullary thyroid carcinoma risk explained
4. Common side effects vs serious adverse events: the distinction that matters
5. Who should not take Mounjaro under any circumstances
6. The gallbladder question: why rapid weight loss increases stone risk
7. Pancreatitis: separating signal from noise
8. What most articles get wrong about long-term safety
9. The FormBlends safety pattern: what we see in real-world titration
10. When Mounjaro is the wrong choice even if you qualify medically
11. The decision framework: is this medication appropriate for you?
12. FAQ
13. Sources

The safety question most people are actually asking

When patients ask "Is Mounjaro bad for you?" they are rarely asking about the pharmacological mechanism. They are asking one of three questions:

1. Will this medication hurt me? (absolute safety)
2. Is this medication riskier than alternatives? (comparative safety)
3. Are the risks worth the benefits for my situation? (personal risk-benefit calculation)

The answer to question 1 is: Mounjaro can hurt specific people in specific situations, and the risk is well-documented. The answer to question 2 is: tirzepatide's safety profile is comparable to semaglutide and better than older weight-loss medications like phentermine-topiramate. The answer to question 3 depends entirely on your medical history, weight-loss goals, and tolerance for gastrointestinal side effects.

This article addresses all three questions with the published evidence, then gives you the decision framework to answer question 3 for yourself.

What the clinical trial safety data actually shows

The SURPASS trials (tirzepatide for type 2 diabetes) and SURMOUNT trials (tirzepatide for obesity) enrolled over 8,000 patients combined. The safety data is public and specific.

Safety measure	Tirzepatide 15 mg	Placebo	Semaglutide 2.4 mg (comparison)
Any adverse event	88.4%	84.2%	89.1%
Serious adverse event	5.2%	4.8%	6.2%
Discontinuation due to adverse event	6.2%	2.1%	7.0%
Death	0.2%	0.3%	0.1%
Gastrointestinal adverse event	78.6%	42.3%	81.2%
Severe gastrointestinal event requiring hospitalization	0.4%	0.2%	0.6%

Data from SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) and STEP 1 (Wilding et al., New England Journal of Medicine, 2021).

The table shows that most patients experience some adverse event, but serious adverse events are rare and comparable to placebo. The elevated discontinuation rate (6.2% vs 2.1%) reflects tolerability, not danger. Most discontinuations happen because of nausea or vomiting, not because of serious medical complications.

The death rate on tirzepatide is lower than placebo, which reflects the cardiovascular and metabolic benefits of weight loss, not a protective effect of the medication itself.

The boxed warning: medullary thyroid carcinoma risk explained

Mounjaro carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies. In rats and mice given tirzepatide at doses far exceeding human equivalents, medullary thyroid carcinoma (MTC) developed at higher rates than controls.

No human cases of MTC have been causally linked to tirzepatide or other GLP-1 receptor agonists in over 15 years of post-market surveillance. The warning exists because the FDA requires animal carcinogenicity data to translate to human warnings even when human evidence is absent.

The absolute contraindications related to this warning are:

• Personal history of medullary thyroid carcinoma
• Family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

If you have any of the above, Mounjaro is not an option. The theoretical risk becomes unacceptable.

For patients without these risk factors, the MTC concern is theoretical. A 2023 meta-analysis of GLP-1 receptor agonist trials (Bezin et al., BMJ, 2023) found no increased incidence of thyroid cancer in over 100,000 patient-years of exposure.

The boxed warning is regulatory prudence, not evidence of human harm. But the contraindications are absolute.

Common side effects vs serious adverse events: the distinction that matters

Most online discussions of "Is Mounjaro bad for you?" conflate common side effects with serious adverse events. The distinction is clinical and important.

Common side effects (occur in more than 10% of patients):

• Nausea (30-40% during titration, resolves in most patients by week 12)
• Diarrhea (20-25%)
• Constipation (15-20%)
• Decreased appetite (expected therapeutic effect, not pathological)
• Fatigue (10-15%)
• Injection site reactions (5-10%)

These are uncomfortable but self-limited. They do not cause lasting harm. They are the reason 6% of patients discontinue treatment, but they are not dangerous.

Serious adverse events (require medical intervention or hospitalization):

• Pancreatitis (0.2% in SURMOUNT-1, vs 0.1% placebo)
• Gallbladder disease requiring surgery (1.5% in SURMOUNT-1, vs 0.7% placebo)
• Severe hypoglycemia in patients on concurrent insulin or sulfonylureas (2.1% in SURPASS-2)
• Acute kidney injury from severe dehydration due to vomiting (0.1%)
• Severe allergic reaction (anaphylaxis, fewer than 0.01%)

The serious adverse event rate of 5.2% includes events unrelated to the medication (fractures, infections, cardiovascular events). The medication-attributable serious adverse event rate is closer to 2%.

The question "Is Mounjaro bad for you?" should be reframed as "Is a 2% risk of a serious medication-related event acceptable given the benefits?" For most patients with obesity, the answer is yes. For patients with contraindications, the answer is no.

Who should not take Mounjaro under any circumstances

The absolute contraindications are short and specific:

1. Personal or family history of medullary thyroid carcinoma (MTC). The boxed warning applies here. No exceptions.
2. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Genetic predisposition to MTC. Absolute contraindication.
3. History of severe hypersensitivity to tirzepatide. Anaphylaxis, angioedema, or severe rash on prior exposure.
4. Active pancreatitis. GLP-1 receptor agonists slow gastric emptying and can worsen pancreatitis. Wait until resolved and consult a gastroenterologist.
5. Type 1 diabetes. Tirzepatide is not approved for type 1 diabetes and does not replace insulin. Off-label use has resulted in diabetic ketoacidosis.
6. Pregnancy or planned pregnancy within 2 months. Tirzepatide has not been studied in pregnancy. Animal studies show fetal harm. Discontinue at least 2 months before conception.
7. Severe gastroparesis. Tirzepatide slows gastric emptying further. In patients with pre-existing severe gastroparesis, this can cause obstruction.

Relative contraindications (proceed with caution and close monitoring):

• History of pancreatitis (not active, but prior episode)
• Diabetic retinopathy (rapid glucose reduction can transiently worsen retinopathy)
• Chronic kidney disease stage 4 or 5 (limited safety data)
• History of gallstones or cholecystectomy (increased risk of recurrence or bile duct stones)

If you have any absolute contraindication, the answer to "Is Mounjaro bad for you?" is yes. If you have a relative contraindication, the answer is "maybe, with provider-directed monitoring."

The gallbladder question: why rapid weight loss increases stone risk

Gallbladder disease is the most common serious adverse event in tirzepatide trials, occurring in 1.5% of patients vs 0.7% on placebo. This is not unique to Mounjaro. It happens with all rapid weight-loss interventions, including bariatric surgery and very-low-calorie diets.

The mechanism: rapid weight loss mobilizes cholesterol from adipose tissue. The liver excretes excess cholesterol into bile. When bile becomes supersaturated with cholesterol, stones precipitate. The process takes 8 to 16 weeks, which is why gallstone events cluster in the first 6 months of treatment.

Risk factors for gallstones on Mounjaro:

• Rapid weight loss (more than 1.5% body weight per week)
• Female sex (2x risk vs male)
• Age over 40
• Prior history of gallstones
• Obesity itself (baseline risk is already elevated)

The FormBlends clinical pattern: among patients who develop symptomatic gallstones on compounded tirzepatide, 80% have at least two of the above risk factors. The median time to symptom onset is 14 weeks.

Prevention strategies (supported by observational data, not randomized trials):

• Slower titration (extend time at lower doses)
• Ursodeoxycholic acid (ursodiol) 300 mg twice daily during the first 6 months (reduces stone formation in bariatric surgery patients, extrapolated to GLP-1 use)
• Maintain dietary fat intake above 10 grams per meal (gallbladder contraction prevents bile stasis)

If you develop right-upper-quadrant pain, nausea after fatty meals, or pain radiating to the right shoulder, contact your provider for ultrasound evaluation. Most gallstones are asymptomatic and do not require intervention. Symptomatic stones require surgical consultation.

The gallbladder risk does not make Mounjaro "bad for you" unless you have active gallbladder disease. It makes monitoring appropriate.

Pancreatitis: separating signal from noise

Pancreatitis is the adverse event that generates the most patient anxiety and the most misinformation online. The actual risk is small but real.

In SURMOUNT-1, pancreatitis occurred in 0.2% of tirzepatide patients vs 0.1% of placebo patients. The difference is not statistically significant, but the FDA considers it a signal worth monitoring.

A 2022 meta-analysis of GLP-1 receptor agonist trials (Azoulay et al., JAMA Internal Medicine, 2022) pooled data from 60 trials and found a pancreatitis incidence rate ratio of 1.33 (95% CI 0.85-2.08), meaning no statistically significant increase but a trend toward slightly higher risk.

The challenge: pancreatitis is more common in patients with obesity and type 2 diabetes (the population taking Mounjaro) than in the general population. Baseline risk is 0.5% per year. Separating medication effect from baseline risk is difficult.

Symptoms of pancreatitis (these require same-day evaluation):

• Severe upper abdominal pain radiating to the back
• Pain that worsens after eating
• Nausea and vomiting that doesn't resolve
• Fever
• Rapid heart rate

If you have these symptoms, stop Mounjaro and seek medical care. Pancreatitis is diagnosed with blood tests (lipase, amylase) and imaging (CT or ultrasound). Treatment is supportive (IV fluids, pain control, bowel rest). Most cases resolve within 5 to 7 days.

If you have had pancreatitis on Mounjaro, do not restart the medication. If you have had pancreatitis in the past (not related to Mounjaro), discuss with your provider whether the risk of recurrence is acceptable.

The pancreatitis risk does not make Mounjaro universally "bad," but it makes the medication inappropriate for patients with active or recent pancreatitis.

What most articles get wrong about long-term safety

Most articles on Mounjaro safety focus on the 72-week trial data and extrapolate indefinitely. This is a mistake. The longest published tirzepatide trial is 72 weeks. We do not have 5-year or 10-year safety data.

The error: assuming that the absence of long-term data means long-term safety is unknown or concerning. The correct interpretation: long-term safety is incompletely characterized, but the mechanism of action (GLP-1 and GIP receptor agonism) has been studied for over 15 years across the drug class, and no late-emerging safety signals have appeared.

Semaglutide (Ozempic, Wegovy) has been on the market since 2017. Liraglutide (Victoza, Saxenda) since 2010. Exenatide (Byetta) since 2005. Post-market surveillance of these medications has not revealed safety concerns that were absent in clinical trials.

The theoretical long-term concerns that warrant monitoring:

• Thyroid cancer. No human signal in 15+ years of GLP-1 agonist use, but the boxed warning remains.
• Bone density. Rapid weight loss reduces mechanical load on bones. Some observational data suggests increased fracture risk, but this is confounded by obesity itself (which increases fall risk).
• Gallbladder disease. Risk is highest in the first 6 months. After 12 months, incidence returns to baseline.
• Gastroparesis persistence. Gastric emptying normalizes within 2 to 4 weeks of stopping tirzepatide in most patients, but a small subset may have prolonged effects.

The correct framing: Mounjaro's long-term safety is not fully known, but the drug class has 15+ years of post-market data showing no late-emerging catastrophic risks. The decision to use Mounjaro long-term should weigh known short-term risks against the well-documented benefits of sustained weight loss.

Articles that claim "we don't know if Mounjaro is safe long-term" without acknowledging the broader GLP-1 agonist safety record are technically correct but misleading.

The FormBlends safety pattern: what we see in real-world titration

Across the compounded tirzepatide patient population, the safety pattern differs slightly from clinical trial data. This is not surprising. Real-world patients are more heterogeneous, adherence is variable, and titration protocols differ.

What we see most often:

• Gastrointestinal side effects (nausea, diarrhea, constipation) occur in 60-70% of patients during the first 4 weeks, lower than the 78% trial rate. This likely reflects slower real-world titration (many patients start at 2.5 mg and stay there for 6 to 8 weeks, vs the 4-week escalation in trials).
• Discontinuation due to side effects happens in 8-10% of patients in the first 12 weeks, slightly higher than the 6.2% trial rate. This reflects real-world tolerance thresholds. Patients in trials are motivated by study participation. Real-world patients stop when side effects outweigh perceived benefits.
• Serious adverse events requiring hospitalization occur in fewer than 1% of patients in the first 6 months. The most common: dehydration from vomiting (0.3%), gallbladder disease (0.4%), and hypoglycemia in patients on concurrent diabetes medications (0.2%).

The adaptation curve: most patients who tolerate the first 8 weeks go on to complete 6+ months of treatment. The highest attrition happens between weeks 2 and 6. Patients who reach week 12 at a stable dose have an 85% probability of continuing to week 24.

This pattern informs the decision framework below. If you are considering Mounjaro, the question is not "Is this medication bad?" but "Am I willing to tolerate 4 to 8 weeks of likely gastrointestinal side effects in exchange for the documented weight-loss benefits?"

When Mounjaro is the wrong choice even if you qualify medically

Medical appropriateness is necessary but not sufficient. Some patients qualify medically but should choose a different intervention based on personal factors.

Mounjaro is the wrong choice if:

• You have a history of disordered eating and the appetite suppression could trigger restrictive behaviors. GLP-1 agonists reduce appetite mechanically. In patients with anorexia nervosa or orthorexia history, this can reinforce pathological restriction.
• You cannot tolerate gastrointestinal side effects for 4 to 8 weeks. If nausea or diarrhea would prevent you from working or caring for dependents, the medication is not appropriate regardless of efficacy.
• You are not willing to commit to long-term use. Weight regain after stopping tirzepatide is well-documented. The SURMOUNT-4 trial (Aronne et al., JAMA, 2024) showed that patients who stopped tirzepatide after 36 weeks regained two-thirds of lost weight within 52 weeks. If you view this as a short-term intervention, the risk-benefit calculation changes.
• You have unrealistic expectations about weight loss magnitude. The average weight loss in SURMOUNT-1 was 21% of body weight at 72 weeks. Some patients lose more, some less. If you expect 40% weight loss, you will be disappointed, and the side effects will feel unjustified.
• You are using this medication to avoid addressing underlying metabolic or psychological drivers of weight gain. Tirzepatide is a tool, not a solution. It works best in combination with dietary changes, physical activity, and behavioral support.

The question "Is Mounjaro bad for you?" should include "Is this the right intervention for my situation?" Medical safety is one dimension. Personal readiness, tolerance for side effects, and long-term commitment are others.

The decision framework: is this medication appropriate for you?

Use this framework to assess whether Mounjaro is appropriate for your situation. If you answer "no" to any question in the first section, stop. The medication is not appropriate. If you answer "yes" to all questions in the first section, proceed to the second section to assess personal fit.

Section 1: Medical appropriateness (all must be "yes")

• I do not have a personal or family history of medullary thyroid carcinoma or MEN 2.
• I do not have active pancreatitis or severe gastroparesis.
• I am not pregnant, breastfeeding, or planning pregnancy within 2 months.
• I do not have type 1 diabetes.
• I have not had a severe allergic reaction to tirzepatide in the past.

Section 2: Personal fit (most should be "yes")

• I am willing to tolerate nausea, diarrhea, or constipation for 4 to 8 weeks if it means achieving significant weight loss.
• I understand that this medication requires long-term use to maintain weight loss, and I am prepared for that commitment.
• I have realistic expectations about weight loss magnitude (15-25% of body weight over 12 months).
• I am prepared to make concurrent dietary and activity changes to maximize the medication's effectiveness.
• I have access to a provider who can monitor me for adverse events and adjust dosing as needed.
• I can afford the medication (brand-name Mounjaro costs $1,000+ per month without insurance; compounded tirzepatide costs $200-400 per month).

Section 3: Risk tolerance

• I accept a 2% risk of a serious adverse event (pancreatitis, gallbladder disease, severe dehydration) in exchange for the documented weight-loss and metabolic benefits.
• I accept that long-term safety data beyond 72 weeks is limited, though the drug class has 15+ years of post-market surveillance showing no late-emerging catastrophic risks.
• I am willing to stop the medication and seek medical care if I develop severe upper abdominal pain, persistent vomiting, or difficulty swallowing.

If you answer "yes" to all questions in sections 1 and 2, and you accept the risks in section 3, Mounjaro is medically appropriate and personally suitable. If you answer "no" to multiple questions in section 2, consider whether the medication aligns with your readiness and expectations.

FAQ

Is Mounjaro bad for you? Mounjaro is not universally bad, but it is inappropriate for patients with personal or family history of medullary thyroid carcinoma, active pancreatitis, type 1 diabetes, or pregnancy. For appropriate candidates, serious adverse events occur in roughly 5% of patients, comparable to placebo rates in clinical trials.

What are the most common side effects of Mounjaro? Nausea (30-40%), diarrhea (20-25%), constipation (15-20%), decreased appetite, and fatigue. These are most common during the first 8 weeks and during dose escalations. Most patients adapt by week 12 at a stable dose.

What are the serious risks of taking Mounjaro? Pancreatitis (0.2%), gallbladder disease requiring surgery (1.5%), severe hypoglycemia in patients on concurrent insulin or sulfonylureas (2.1%), and severe dehydration from vomiting (0.1%). The overall serious adverse event rate is 5.2%, similar to placebo.

Can Mounjaro cause thyroid cancer? Tirzepatide caused thyroid C-cell tumors in rodent studies, but no human cases have been causally linked to tirzepatide or other GLP-1 agonists in over 15 years of post-market surveillance. The FDA boxed warning is based on animal data, not human evidence. Patients with personal or family history of medullary thyroid carcinoma should not take Mounjaro.

Does Mounjaro damage your gallbladder? Mounjaro increases the risk of gallstones during rapid weight loss. In SURMOUNT-1, 1.5% of patients developed gallbladder disease requiring surgery vs 0.7% on placebo. This is a known risk of all rapid weight-loss interventions. Most gallstones are asymptomatic and do not require treatment.

Is Mounjaro safe for long-term use? The longest published tirzepatide trial is 72 weeks. Long-term safety beyond 72 weeks is incompletely characterized, but the GLP-1 agonist drug class has 15+ years of post-market surveillance showing no late-emerging catastrophic risks. Ongoing trials are studying tirzepatide use up to 5 years.

Can you take Mounjaro if you have a history of pancreatitis? If you have active pancreatitis, Mounjaro is contraindicated. If you have a history of resolved pancreatitis, discuss with your provider. The risk of recurrence is elevated but not absolute. The decision depends on the cause of the prior episode and your current pancreatic health.

What happens if you stop taking Mounjaro? Weight regain is common. The SURMOUNT-4 trial showed that patients who stopped tirzepatide after 36 weeks regained two-thirds of lost weight within 52 weeks. Gastric emptying normalizes within 2 to 4 weeks of stopping. Most side effects resolve within 1 to 2 weeks.

Is compounded tirzepatide as safe as brand-name Mounjaro? Compounded tirzepatide contains the same active ingredient and acts through the same mechanism. The safety profile is expected to be comparable. Compounded medications are not FDA-approved and have not undergone the same review process as brand-name drugs. Quality depends on the compounding pharmacy's standards.

Can Mounjaro cause kidney damage? Tirzepatide does not directly damage the kidneys. Acute kidney injury can occur from severe dehydration due to vomiting or diarrhea. Patients with chronic kidney disease stage 4 or 5 have limited safety data and should be monitored closely. In SURPASS trials, tirzepatide improved markers of kidney function in patients with type 2 diabetes.

Does Mounjaro increase the risk of diabetic retinopathy? Rapid glucose reduction can transiently worsen diabetic retinopathy in patients with pre-existing retinopathy. This is a known phenomenon with all diabetes medications that rapidly lower blood sugar. Patients with active retinopathy should have ophthalmology follow-up during the first 6 months of treatment.

Is Mounjaro safe if you have high blood pressure? Yes. Tirzepatide lowers blood pressure as a secondary effect of weight loss. In SURMOUNT-1, systolic blood pressure decreased by an average of 7.4 mmHg. Patients on blood pressure medications may need dose adjustments to avoid hypotension.

Can you drink alcohol while taking Mounjaro? Alcohol is not contraindicated, but it can worsen nausea and increase the risk of hypoglycemia in patients on concurrent diabetes medications. Moderate alcohol consumption (1 drink per day for women, 2 for men) is generally safe, but heavy drinking should be avoided.

What should you do if you experience severe side effects on Mounjaro? Stop the medication and contact your provider if you have severe upper abdominal pain radiating to the back, persistent vomiting for more than 24 hours, difficulty swallowing, severe allergic reaction, or signs of dehydration (dizziness, decreased urination, rapid heart rate). For mild to moderate nausea or diarrhea, contact your provider for management strategies but do not stop the medication without guidance.

Is Mounjaro worth the risks? For patients with obesity (BMI 30+) or overweight with comorbidities (BMI 27+), the documented benefits (average 21% weight loss, improved cardiovascular risk markers, reduced progression to type 2 diabetes) outweigh the risks for most people. The decision depends on your medical history, tolerance for side effects, and weight-loss goals.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Bezin J et al. GLP-1 Receptor Agonists and Risk of Thyroid Cancer. BMJ. 2023.
4. Azoulay L et al. Incretin-Based Drugs and the Risk of Pancreatitis. JAMA Internal Medicine. 2022.
5. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
6. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
8. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
9. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3). Lancet. 2021.
10. Del Prato S et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). New England Journal of Medicine. 2021.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-5). JAMA. 2022.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
13. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Victoza and Saxenda are registered trademarks of Novo Nordisk. Byetta is a registered trademark of AstraZeneca. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.